Lilly’s experimental oral weight‑loss pill, orforglipron, helped patients largely maintain prior weight loss after they switched from injectable GLP‑1 treatments such as Novo Nordisk’s Wegovy and Lilly’s own Zepbound, the company said, after a late‑stage trial met its primary endpoint.
The ATTAIN‑MAINTAIN study followed more than 300 adults who had completed 72 weeks on high‑dose injectables and then were randomised to receive orforglipron or placebo for 52 weeks; those who took the pill regained only modest weight on average compared with placebo recipients. Patients who switched from Wegovy regained about 0.9 kilograms on average after a year, while those switching from Zepbound regained around 5 kilograms, figures Lilly reported.
The trial showed orforglipron was superior to placebo at maintaining weight loss and met its primary endpoint, prompting Lilly to file for regulatory approval of the oral GLP‑1 agent; the company has highlighted the pill as a less invasive, potentially more accessible option for long‑term weight management. Safety data presented so far did not reveal new liver concerns, and rates of adverse-event-linked discontinuation were similar between treatment groups in the cohorts studied, according to trial summaries.
Researchers and company executives say the findings are important because many patients who stop injectable GLP‑1 therapies regain substantial weight within months to a year and an effective oral maintenance therapy could reduce the need for ongoing injections or provide an easier long‑term option. Observers will be watching for full peer‑reviewed publication of the ATTAIN‑MAINTAIN results and for regulatory decisions on orforglipron, which could reshape treatment choices in obesity management if approved.
